Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR-2041 for Vulvovaginal Atrophy
NCT00361569Phase 3Completed
- Sponsor
- Duramed Research
- Start
- Aug 2006
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of conjugated estrogens in Vulvovaginal atrophy (VVA) (4 arms), sponsored by Duramed Research. Primary endpoints: Mean Change in the Symptom Identified by the Patient to be Most Bothersome at 12 weeks, Mean Change in Vaginal pH at 12 weeks and 1 more. Started Aug 2006; status: completed.
02
Drugs
conjugated estrogens
03
Conditions
Vulvovaginal atrophy (VVA)
Beyond the preview
Go deeper on NCT00361569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361569.